5 studies found for:    17625124 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Condition: Chronic Hepatitis C
Intervention: Drug: Pegylated interferon alfa-2a + ribavirin
2 Withdrawn 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C
Condition: Chronic Hepatitis C
Intervention: Drug: pegylated interferon alpha 2a + ribavirin
3 Terminated Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
Condition: Hepatitis C, Chronic
Interventions: Drug: pegylated interferon alpha-2b;   Drug: Ribavirin;   Drug: pegylated Interferon alpha-2b
4 Terminated EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
Condition: Chronic Hepatitis C
Intervention: Drug: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
5 Completed ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.
Condition: Hepatitis C, Chronic
Interventions: Drug: peginterferon alfa-2a [Pegasys];   Drug: Copegus

Indicates status has not been verified in more than two years